NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter Earnin ...

400 300 200 D Nov. OGI Sep Aug Jul Jun May Apiruk Seeking Alpha, TradingView The share price of TG was riding high last year following Briumvi's launch and while the management team did not provide revenue guidance during the initial launch period, their comments were (with benefit of hindsight) interpreted as Briumvi performing much better than it, in reality, was. The hard landing happened when the company announced second quarter results in early August 2023, slightly missing the revenue consensus and an ...

ABOUT TG THERAPEUTICS NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET. TG Therapeutics is a fully integrated, commercial stage, biopharmaceutic ...

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B- ...

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. Link to Poster Presentation: A Post-Marketing Study Evaluating the Presence and Concentrat ...

ABOUT THE ULTIMATE I & II PHASE 3 TRIALS ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator- controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or terifl ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 (State or other jurisdiction of incorp ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - President and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Edward White - H.C. Wainwright Roger Song - Jefferies Matthew Kaplan - Ladenburg Thalmann Mayank Mamtani - B. Riley Securities, Inc. Prak ...

Exhibit 99.1 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Conference call to be held today, May 1, 2024, at 8:30 AM ET First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New York, NY, (May 1, 2024) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number 1-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (Stat ...